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Abstract Pasireotide has a broader somatostatin receptor
binding profile than other somatostatin analogues. A
16-week, Phase II trial showed that pasireotide may be an
effective treatment for acromegaly. An extension to this trial
assessed the long-term efficacy and safety of pasireotide. This
study was an open-label, single-arm, open-ended extension
study (primary efficacy and safety evaluated at month 6).
Patients could enter the extension if they achieved bio-
chemical control (GH B 2.5 lg/L and normal IGF-1) or
showed clinically relevant improvements during the core
study. Thirty of the 60 patients who received pasireotide
(200–900 lg bid) in the core study entered the extension. At
extension month 6, of the 26 evaluable patients, six were
biochemically controlled, of whom five had achieved control
during the core study. Normal IGF-1 was achieved by 13/26
patients and GH B 2.5 lg/L by 12/26 at month 6. Nine
patients received pasireotide for C24 months in the exten-
sion; three who were biochemically controlled at month 24
had achieved control during the core study. Of 29 patients
with MRI data, nine had significant (C20 %) tumor volume
reduction during the core study; an additional eight had sig-
nificant reduction during the extension. The most common
adverse events were transient gastrointestinal disturbances;
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hyperglycemia-related events occurred in 14 patients.
Twenty patients had fasting plasma glucose shifted to a higher
category during the extension. However, last available glu-
cose measurements were normal for 17 patients. Pasireotide
has the potential to be an effective, long-term medical treat-
ment for acromegaly, providing sustained biochemical con-
trol and significant reductions in tumor volume.
Keywords Acromegaly  Efficacy  Pasireotide  Safety 
SOM230  Somatostatin analogue
Introduction
Acromegaly is a serious disorder of growth hormone (GH)
hypersecretion that usually develops over many years. In
more than 90 % of patients, the excessive GH level is
produced by a pituitary somatotroph adenoma [1]. GH
induces synthesis of insulin-like growth factor 1 (IGF-1)
via hepatic GH receptors; elevated levels of GH and IGF-1
can lead to metabolic dysfunction and somatic growth [2].
Control of GH and IGF-1 is important in patients with
acromegaly if mortality is to be reduced to expected levels
[3]. Transsphenoidal surgery is the recommended first-line
treatment for many patients with acromegaly, particularly
those with microadenomas [4, 5]. However, 40–60 % of
patients with acromegaly will experience persistent or
recurrent disease following surgery, necessitating addi-
tional therapy [1, 4, 6].
Somatostatin analogues are the first-line medical treat-
ment for patients with acromegaly. Compared with the
universal somatostatin receptor subtype (sst) binding of
somatostatin, the currently available somatostatin ana-
logues octreotide and lanreotide act preferentially at the
somatostatin receptor sst2 [7–9]. However, pituitary tumors
in patients with acromegaly express both sst2 and sst5 [10].
A somatostatin analogue with a broader binding profile
than octreotide or lanreotide may therefore provide addi-
tional therapeutic benefits.
Pasireotide (SOM230) is a multireceptor-targeted somato-
statin analogue with a unique receptor binding profile,
having high affinity for sst2 and sst5, as well as sst1 and sst3
[7, 10]. Therefore, it has the potential to be a more effective
therapy for acromegaly than octreotide or lanreotide [11].
In a 16-week, Phase II study of 60 patients with active
acromegaly, biochemical control of GH and IGF-1 levels
was achieved by 27 % of patients after 12 weeks of
treatment with subcutaneous (sc) pasireotide, and 39 % of
patients achieved significant (C20 %) tumor volume
reduction [12]. This paper presents results from the open-
ended extension period of this Phase II study and evaluates
the long-term efficacy and safety of pasireotide in patients
with acromegaly.
Materials and methods
Study design
This open-label, multicenter, single-arm extension study
(ClinicalTrials.gov NCT00171730) was a planned exten-
sion to a 16-week, multicenter, randomized, open-label,
crossover Phase II study (the core study; ClinicalTrials.gov
NCT00088582) [12]. During the core study, patients
(n = 60) received 4 weeks’ treatment with octreotide
100 lg sc tid followed by 12 weeks’ treatment with
pasireotide 200, 400 and 600 lg sc bid for 1 month each in
random order. To be included in this extension, patients
either achieved biochemical control after at least 1 month
of pasireotide at any of the three doses in the core study or
achieved clinical benefit as determined by the investigator.
Patients who achieved biochemical control during the core
study initiated therapy in the extension study with the
lowest pasireotide dose which provided biochemical con-
trol. Patients who did not achieve biochemical control but
experienced clinical benefit during the core study initiated
therapy in the extension study with pasireotide 600 lg sc
bid. Dose adjustments were permitted in response to sub-
optimal biochemical control, with a maximum permitted
dose of pasireotide of 900 lg sc bid.
During the extension study, pasireotide was administered
for as long as treatment benefit was derived. Patients were
discontinued from the extension study if they received any
other therapeutic intervention for the treatment of acro-
megaly, failed to demonstrate continued benefit from pa-
sireotide, experienced any unacceptable adverse event (AE)
or were not compliant with the dosing schedule. Therefore,
end of study was unique for each patient.
This study was approved by the Independent Ethics
Committee, Institutional Review Board or Research Ethics
Board (IEC/IRB/REB) for each study center. The study
was conducted according to the ethical principles of the
Declaration of Helsinki. All patients provided written
informed consent.
Patients
Patients aged 18–80 years who completed the core study
were eligible to enter the extension phase if they had
achieved biochemical control (GH B 2.5 lg/L and nor-
malized IGF-1) after at least 1 month of pasireotide
administration at any of the three doses, or if they showed
clinically relevant improvement according to investigator
judgment from at least one of the pasireotide regimens.
Patients who experienced any unacceptable AEs, who
experienced tumor compression of the optic chiasm caus-
ing visual-field defects, or who required surgical inter-
vention as a result of tumor compression during the core
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study were excluded from the extension study. Patients
were also excluded if they developed impaired glucose
tolerance or diabetes mellitus during the core study that did
not resolve when pasireotide treatment was stopped (three
patients were excluded from entering the extension study
due to diabetes mellitus or hyperglycemia), or if they
experienced cardiovascular morbidity (e.g. congestive
heart failure, unstable angina), symptomatic cholelithiasis
or liver disease during the core study.
Endpoints
The primary efficacy evaluation was the percentage of
patients achieving biochemical response defined as GH level
B2.5 lg/L and normal IGF-1 (age and sex matched) at
month 6 in the extension study. The proportions of patients
with control of GH alone or IGF-1 alone were also recorded.
GH and IGF-1 levels were evaluated every 3 months
throughout the extension study. To calculate mean circu-
lating GH levels, blood samples were taken at 30, 60, 90 and
120 min after the morning administration of pasireotide.
IGF-1 levels were calculated as the mean of two measure-
ments taken 30 and 1 min before pasireotide administration.
Pituitary magnetic resonance imaging (MRI) scans were
performed at the screening visit before the core study (pre-
octreotide), at the end of the core study (after 3 months of
pasireotide), and at the last visit or every 6 months during
the extension study. Digital images were assessed using
established techniques and criteria by a central neuroradi-
ologist. Significant tumor response was defined as a C20 %
decrease in tumor volume.
Acromegaly symptom severity was recorded. The severity
of headache, perspiration, paresthesia, fatigue, osteoarthral-
gia and carpal tunnel syndrome was recorded on a five-point
scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe,
4 = very severe). Sleep apnea was assessed using the
Epworth Sleepiness Scale [13], which assesses the level of
sleepiness in different situations on a four-point scale
(0 = would never doze, 1 = slight chance of dozing,
2 = moderate chance of dozing, 3 = high chance of dozing).
Safety and tolerability were assessed every 3 months. The
primary safety evaluation was based on 6 months of pasire-
otide treatment and reported annually thereafter. Assess-
ments included AEs, laboratory findings, electrocardiogram
(ECG) recordings and gallbladder ultrasound. AEs were
classified according to severity (Common Terminology
Criteria for Adverse Events, CTCAE v3.0 [14]) and rela-
tionship with study drug and were reported by preferred term.
Hormone assays
Serum GH and IGF-1 were measured by a central labora-
tory using validated chemiluminescent immunometric
assays (DPC Immulite 2000; Diagnostic Products Corp.,
Los Angeles, CA). The lower limit of detection for GH was
0.1 lg/L, with intra- and inter-assay coefficients of varia-
tion B10 %. For IGF-1, the lower limit of detection was
25 lg/L, with intra- and inter-assay coefficients of varia-
tion B8.3 %. Normal values for IGF-1 were 182–780,
114–492, 90–360 and 71–290 lg/L in patients aged 16–24,
25–39, 40–54, and C55 years, respectively.
Pharmacokinetics
Blood samples for pharmacokinetic assessments were
collected at each scheduled visit during GH assessment
(1 min pre-dose and 1 and 2 h post-dose). Plasma con-
centrations of pasireotide were measured using a validated
radioimmunoassay with a lower limit of detection of
0.15 ng/mL.
Statistical methods
Efficacy analysis was based on patients who had at least
two GH measurements and both pre-dose IGF-1 measure-
ments at the corresponding visit. The safety population
included all patients who had received pasireotide sc in the
extension study.
Results from all centers were combined. Response rates
and 95 % confidence intervals (CI) were provided by dose.
Results
Patients
Thirty of the 60 patients who received pasireotide in the
core study entered the extension. The core and extension
studies had individual study protocols, resulting in an
interphase dosing holiday of variable length depending on
study site. Six patients had no dosing holiday, three
patients received octreotide sc treatment between the end
of the core study and entering the extension, and 21
patients received no treatment between the end of the core
study and entering the extension [the mean duration of the
dosing holiday was 43.6 days in these patients (range
12–220 days)].
The median age of the patients enrolled in the extension
study was 45.1 years (Table 1). Females comprised 53 %
of the extension study population, compared with 45 % in
the core study. Before enrollment in the core study, 73 %
of extension patients received treatment with somatostatin
analogues and 63 % underwent pituitary surgery for acro-
megaly (these values were 67 and 58 %, respectively, in
the core study population). Thirteen percent of patients in
the extension were de novo and had not received prior
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medical, radiation or surgical treatment for acromegaly
(Table 1); the corresponding proportion for the core study
was 23 %.
Of the 30 patients who entered the extension, eight
discontinued because of an unsatisfactory therapeutic
effect, four discontinued because of AEs (three for hyper-
glycemia and one for colon cancer and gallbladder polyp),
and three withdrew consent. An additional eight patients
discontinued in order to enroll in another pasireotide study
(NCT00446082, CSOM230C2110). The median duration
of treatment was 22.7 months (range 4–61 months).
Effects of pasireotide on GH and IGF-1 levels
A wide dose range from 400 to 1,800 lg daily was
observed across the 30 patients who entered the extension.
However, for individual patients, the extent of dose titra-
tion in the extension was relatively small.
After 3 months of treatment with pasireotide sc (end of
core study), the mean ± SD GH level was 8.2 ± 10.1 lg/L,
with a mean change (±SD) in GH from pasireotide sc
baseline of -1.1 ± 11.5 lg/L (n = 27 evaluable patients).
By month 21 of the extension, the mean GH level had
decreased to 4.9 ± 5.8 lg/L, a mean (±SD) change from
pasireotide sc baseline of -1.7 ± 5.6 lg/L (12 evaluable
patients). The mean IGF-1 level was 612 ± 209 lg/L at
the pasireotide sc core study baseline and 671 ± 201 lg/L
after 3 months [end of core study (n = 30 for both)]. At
month 21 of the extension, the mean IGF-1 level had
decreased to 296 ± 112 lg/L (n = 12), a mean (±SD)
change from baseline of -279 ± 160 lg/L.
In the primary efficacy analysis at month 6 of the
extension, six of the 26 evaluable patients [with at least two
GH measurements and two predose IGF-1 samples (23 %;
95 % CI, 9.0–43.6 %)] had full biochemical control
(defined as GH B 2.5 lg/L and age- and sex-normalized
IGF-1). Five of these patients had already achieved bio-
chemical control during the core study, and one patient
achieved control for the first time during the study. Of the
six patients with full biochemical control, four were
receiving pasireotide 1,200–\1,500 lg/day during the
study, one was receiving pasireotide \1,200 lg/day, and
one was receiving pasireotide C1,500 lg/day. At month 6
of the extension, 50 % of evaluable patients (13/26) had
normal IGF-1 levels, four of whom achieved control for the
first time during the extension. A similar proportion of
patients (46 %, 12/26) had GH B 2.5 lg/L at month 6, one
of whom achieved control for the first time during the
extension study.
Nine patients continued in the extension study for at
least 24 months. At month 24, over half of the patients
(56 %, 5/9) had normal IGF-1 and the same number had
GH B 2.5 lg/L. Three patients (33 %) achieved bio-
chemical control of both GH and IGF-1 levels, all of whom
were receiving a daily pasireotide dose of between 1,200
and 1,500 lg.
Effect of pasireotide on tumor volume
Of the 30 patients who entered the extension study, 29
underwent a baseline MRI on entry into the core study. Of
these 29 patients, 17 (58.6 %) had achieved a significant
(C20 %) tumor volume reduction from core baseline to last
assessment. Of the 20 patients without significant tumor
volume reduction before the start of the extension study,
five subsequently experienced significant tumor volume
reduction by month 6, and an additional two patients
achieved significant tumor volume reduction by month 24.
No patient had a C20 % increase in tumor volume
during the core study, and none of the patients enrolled in
the extension study had a C20 % increase between core
baseline and month 6 of the extension study. At month 6 of
the extension study, two (50.0 %) of the four patients with
full biochemical control and two (18.2 %) of the 11
patients without full biochemical control had a C20 %
decrease in tumor volume from extension baseline.
Between core baseline and the last available assessment in
the extension study, 12/16 (75.0 %) responders and 5/13
(38.5 %) non-responders had at least a C20 % decrease in
Table 1 Summary of core baseline demographics and baseline
characteristics of all patients receiving at least one dose of pasireotide
in the extension study
Overall population
(n = 30)
Age (years)
Median (range) 45.1 (21–84)
Sex
Female, n (%) 16 (53.3)
Race, n (%)
Caucasian 26 (86.7)
Other 4 (13.3)
Previous treatment for acromegaly, n (%)
De novoa 4 (13.3)
Previous somatostatin analogue treatment 22 (73.3)
Previous surgery 19 (63.3)
Previous radiotherapy 6 (20.0)
Time since diagnosis (years)b
\1 5 (16.7)
1 to \5 12 (40.0)
5 to \10 7 (23.3)
C10 6 (20.0)
a No prior medical, radiation or surgical treatment for acromegaly
b Time between diagnosis of acromegaly and the beginning of the
core study
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tumor volume (Fig. 1) and one non-responder had a C20 %
increase in tumor volume. Of the five non-responders who
had a C20 % decrease in tumor volume, three had
decreases in GH and IGF-1 from core baseline.
Figure 2 shows the MR images of a patient with tumor
volume reduction in the core study who achieved further
tumor volume reduction with extended pasireotide treatment.
Effect of pasireotide on symptoms of acromegaly
During the extension study, the number of patients with an
absence of headache, fatigue, perspiration and osteoarth-
ralgia approximately doubled (Fig. 3). For each of the
symptoms assessed, more than 50 % of patients
experienced no or mild symptoms at their last available
assessment. No patients had very severe headache, fatigue
or perspiration at their last available assessment. There
were no clear changes in the severity of carpal tunnel
syndrome or paresthesia over time.
Pharmacokinetics
Plasma concentrations of pasireotide typically peaked at
1 h post-dose, based on the data points available pre-dose
and 1 and 2 h post-dose. The dose-normalized trough
concentration–time profiles from individual patients are
shown in Supplemental Fig. 1. Pasireotide exposure tended
to be stable over time in most patients.
Safety and tolerability
All patients experienced at least one AE that was consid-
ered related to the study drug. Most AEs were mild to
moderate in severity and resolved spontaneously during
continued treatment with pasireotide. AEs that were sus-
pected to be drug related were generally those expected for
a somatostatin analogue in this patient population, i.e.
mostly transient gastrointestinal disturbances, with the
exception of the degree of hyperglycemia-related AEs
(Table 2).
In total, hyperglycemia-related AEs were reported in 12
patients (suspected of study drug relationship), nine of
whom experienced more than one hyperglycemia-related
event. Of the five patients who experienced AEs of diabetes
mellitus, four had a previous history of glucose disorders.
The majority of the hyperglycemia-related events were
mild to moderate in severity and were managed with
appropriate treatment.
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Fig. 2 Coronal T1 MR images of a patient, illustrating significant tumor volume reduction during treatment with pasireotide
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No deaths occurred during the study. Seven patients
experienced serious AEs (SAEs), two of which were con-
sidered related to study drug (worsening of diabetes mel-
litus and cholecystitis). One patient with pre-existing
diabetes mellitus had an SAE of worsening diabetes mel-
litus, which was thought to be related to the study drug and
which required insulin therapy. Two patients had SAEs of
new-onset hyperglycemia, which was not suspected to be
related to the study drug. Four patients discontinued pa-
sireotide because of AEs: three because of hyperglycemia
or diabetes mellitus, and one because of cholecystitis and
colon cancer. Two of the observed cases of hyperglycemia
or diabetes mellitus that led to discontinuation were
thought to be related to the study drug, as was the
cholecystitis.
The mean ± SD fasting plasma glucose (FPG) level was
5.36 ± 0.96 mmol/L (96.6 ± 17.3 mg/dL) at extension
baseline, 5.86 ± 1.54 mmol/L (106 ± 27.7 mg/dL) at month
6, and 5.86 ± 2.45 (106 ± 44.1 mg/dL) at month 9 of the
extension. Most patients (n = 20) exhibited a shift to a higher
FPG category at some point during the extension study,
although many returned to the same category or improved
category by their last visit. Of the 17 patients who had an FPG
level\5.6 mmol/L (\100 mg/dL, normal glucose tolerance)
at extension baseline, 11 patients had a shift to a higher FPG
category at some point during the extension; eight had their
highest recorded FPG level between 5.6 and 6.9 mmol/L (100
and \126 mg/dL, impaired fasting glucose), and three had
their highest level at C7.0 mmol/L (C126 mg/dL, diabetes
mellitus). When looking at their last available value, 13 of the
17 patients had normal glucose, three had impaired fasting
glucose and one had diabetes mellitus (Table 3). Twelve
patients had impaired fasting glucose at extension baseline. Of
these, nine had their highest recorded value at C7.0 mmol/L
(C126 mg/dL, diabetes mellitus). Based on their last available
value, one of these 12 patients remained in the impaired
fasting glucose category, seven had an increase in FPG cate-
gory to diabetes mellitus, and four patients had an improve-
ment, being shifted from the impaired fasting glucose to the
normal glucose category (Table 3).
Modest increases in mean HbA1c levels from baseline of
the extension phase were observed during the study. HbA1c
levels increased from a mean ± SD value of 6.16 ± 0.56 %
at extension baseline to 6.82 ± 1.51 % and 6.32 ± 0.68 %
at months 6 and 9 of the extension, respectively.
At the last available assessment in the extension study,
gallstones were detected in 11 patients, nine of whom had
gallstones at extension baseline.
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Fig. 3 Summary of acromegaly symptom severity at extension baseline and end of the extension study
Table 2 AEs (by preferred term) with a suspected study drug rela-
tionship reported in C5 % of patients
Overall patient
population
N = 30
n (%)
Diarrhea 14 (46.7)
Nausea 10 (33.3)
Abdominal pain 6 (20.0)
Flatulence 6 (20.0)
Diabetes mellitus 5 (16.7)
Dizziness 5 (16.7)
Cholelithiasis 4 (13.3)
Type 2 diabetes mellitus 4 (13.3)
Increased blood glucose 3 (10.0)
Esophageal spasm 2 (6.7)
Fatigue 2 (6.7)
Hypoglycemia 2 (6.7)
Arthralgia 2 (6.7)
Paresthesia 2 (6.7)
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Electrocardiogram conduction intervals were generally
within normal ranges at all visits. One patient had a newly
occurring QTcF [ 450 ms during the extension study,
which decreased to B450 ms at subsequent ECG evalua-
tions. Overall, 17 patients had ECGs with at least one
abnormality, but in six cases the overall ECG interpretation
was considered to be normal. Nine patients had at least one
episode of sinus bradycardia, of whom three had sinus
bradycardia at the last study visit.
Discussion
This Phase II extension study showed that, following
9 months of pasireotide therapy (3 months in the core
study and 6 months in the extension study), 23 % (6/26) of
patients with acromegaly achieved biochemical control
(defined as GH B 2.5 lg/L and IGF-1 within age- and sex-
matched limits).The response rate observed in the exten-
sion is similar to that seen in the core study (27 %) after
3 months’ pasireotide treatment [12] and is consistent with
the results of earlier studies of somatostatin analogues that
used this definition of biochemical control [15–17]. These
earlier studies reported response rates of 17–27 % after
1 year of therapy. In the present study, 50 % of patients
achieved IGF-1 normalization alone and 46 % achieved
GH control alone following 9 months of pasireotide ther-
apy. Compared with the core study, an additional five
patients achieved GH and/or IGF-1 control for the first time
during the extension study, which suggests that extending
pasireotide treatment beyond 3 months may be required to
achieve full biochemical control in certain patients.
Current treatment guidelines by the Acromegaly Con-
sensus Group define optimal disease control as normal
IGF-1 for age and sex and a GH level \1.0 lg/L from a
random GH measurement [18, 19]. This current GH cut-off
was defined considering modern GH assays that use the
World Health Organization calibrator [18, 19]. Earlier
studies measuring GH by older immunoassays indicated
that a random GH level \2.5 lg/L and normal IGF-1 for
age and sex is associated with normal life expectancy [3,
20]. This older GH cut-off has continued to be used in
recent studies evaluating the effect of treatment in patients
with acromegaly and was used in the current study as
availability of modern assays with the current WHO cali-
brator was limited at the time of study initiation.
Consistent with previous reports on long-term somato-
statin analogue therapy in acromegaly [17, 21–23],
pasireotide resulted in significant and ongoing reductions
in tumor volume throughout the extension phase of the
study. Fifty-nine percent of patients achieved a significant
(C20 %) reduction in tumor volume over the course of the
core and extension studies. Moreover, a subset of patients
who experienced significant tumor volume reduction dur-
ing the core study went on to achieve further reductions in
tumor volume during the extension phase. This suggests
that patients entering the extension period benefited from
continued therapy and that long-term pasireotide treatment
is effective in reducing the volume of pituitary adenomas.
A significant reduction in tumor volume was more com-
monly observed in patients with biochemical control than
in uncontrolled patients. However, a reduction of at least
20 % in tumor volume was seen in 5/13 (38.5 %) patients
who did not achieve biochemical control. Additional
studies that further investigate the relationship between
biochemical control and tumor volume under pasireotide
treatment are thus warranted.
In addition to biochemical control and reductions in
tumor volume, this study showed that long-term pasireotide
treatment is associated with long-term improvements in the
symptoms of acromegaly, including headache, fatigue,
perspiration and osteoarthralgia. This is consistent with
the results of previous studies that showed significant
improvements in the symptoms of acromegaly following
12 months’ treatment with octreotide LAR [24]. In asso-
ciation with improved detection methods and visualization
Table 3 Shift tables of fasting
plasma glucose following
treatment with pasireotide sc
Blood glucose levels were based
on ADA criteria. The Total
column shows the number of
patients at baseline within a
particular category, and the
middle three columns show the
number of patients within a
given category on treatment
Baseline level \5.6 mmol/L
(\100 mg/dL) (%)
5.6 and 6.9 mmol/L
(100–\126 mg/dL) (%)
C7.0 mmol/L
(C126 mg/dL) (%)
Total (%)
Highest post-baseline value
\5.6 mmol/L 6 (20.0) 8 (26.7) 3 (10.0) 17 (56.7)
5.6–6.9 mmol/L 0 3 (10.0) 9 (30.0) 12 (40.0)
C7.0 mmol/L 0 0 1 (3.3) 1 (3.3)
Total 6 (20.0) 11 (36.7) 13 (43.0) 30 (100)
Last available post-baseline value
\5.6 mmol/L 13 (43.3) 3 (10.0) 1 (3.3) 17 (56.7)
5.6–6.9 mmol/L 4 (13.3) 1 (3.3) 7 (23.3) 12 (40.0)
C7.0 mmol/L 0 0 1 (3.3) 1 (3.3)
Total 17 (56.7) 4 (13.3) 9 (30.0) 30 (100)
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of the tumor, these benefits of treatment have contributed
to the improvements seen in acromegaly [25].
Adverse events were mostly similar to those encountered
with conventional somatostatin analogues: predominantly
mild to moderate gastrointestinal disorders that resolved
during continued pasireotide treatment. Hyperglycemia-
related AEs were reported in 12/30 (40 %) patients. Disor-
ders of glucose metabolism have previously been reported
during treatment of acromegaly with somatostatin analogues
[26, 27], including pasireotide [12]. In addition, patients
with acromegaly are known to be predisposed to changes in
glucose metabolism [28], which in turn leads to a higher
prevalence of diabetes mellitus and glucose intolerance
compared with the general population [29].
In the present study, most patients exhibited a shift to a
higher FPG category at some point during the extension
study, with eight patients worsening to impaired glucose
tolerance (5.6–6.9 mmol/L) and 12 patients worsening to
glucose levels C7.0 mmol/L. However, many returned to
the same category or improved by their last visit, with
57 % of patients having glucose levels \5.6 mmol/L as
their last available value, the same proportion as at
extension baseline. Whether these improvements in FPG
category at the end of the study are due to some tachy-
phylaxis or due to changes in antidiabetic medication
cannot be distinguished. Modest increases in HbA1c levels
were also observed (6.16 % at extension baseline to 6.82 %
at month 6). Additional studies have been conducted to
determine the underlying mechanisms of pasireotide-asso-
ciated hyperglycemia and to evaluate the effects of anti-
diabetic drugs on glucose metabolism in pasireotide-treated
healthy volunteers [30]. These have shown that pasireotide-
associated hyperglycemia is related to decreases in insulin
secretion and incretin hormone response. Pasireotide
appears to have minimal impact on glucagon secretion and
no effect on insulin sensitivity.
In conclusion, pasireotide shows promise as a long-term
medical treatment for acromegaly, providing sustained
biochemical control and significant reductions in pituitary
tumor volume. A randomized, multicenter Phase III trial is
evaluating the efficacy of pasireotide LAR compared with
that of octreotide LAR, which is the current standard of
care in patients with acromegaly.
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